亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Novel Live Recombinant Booster Vaccine against Tuberculosis

技术优势: The new vaccine and strategy are more potent than currently commercially available vaccines in protecting against pulmonary tuberculosis. The bacteria-based booster vaccine invention provides more potent protection against TB infection than protein in adjuvant vaccinations or adenovirus-based vaccines. The bacteria-based vaccine does not require purification from cell culture and is therefore easier and cheaper to manufacture than virus-vectored vaccines.

技术应用: Vaccination for TB.

详细技术说明: In an effort to improve the potency of BCG protection, researchers at UCLA developed a novel vaccine vector system for delivery of TB proteins. This system exploits a live, attenuated bacterial vector to deliver immunizing proteins. The novel booster vaccine can be administered after BCG or similar vaccination. In animal models, use of the novel vaccine induced greater protective immunity than either boosting with purified protein in adjuvant or boosting with recombinant viruses containing the same protein.

*Abstract: Researchers at UCLA have developed a novel vaccination strategy against tuberculosis in humans and animals. The invention also details the generation of a vaccine against leprosy and other mycobacterial diseases in humans and animals.

*IP Issue Date: Jul 3, 2018

*Principal Investigation: Name: Marcus Horwitz
Department:

Name: Qingmei Jia
Department:

附加资料: Patent Number: US20130101614A1
Application Number: US13704133A
Inventor: Horwitz, Marcus A. | Jia, Qingmei
Priority Date: 15 Jun 2010
Priority Number: US20130101614A1
Application Date: 13 Dec 2012
Publication Date: 25 Apr 2013
IPC Current: A61K003904
US Class: 4241901 | 4352523
Assignee Applicant: The Regents of the University of California
Title: NOVEL LIVE RECOMBINANT BOOSTER VACCINE AGAINST TUBERCULOSIS
Usefulness: NOVEL LIVE RECOMBINANT BOOSTER VACCINE AGAINST TUBERCULOSIS
Summary: For treating mycobacterial diseases such as tuberculosis in humans and animals; and for preventing or reducing the possibility of infection caused by Mycobacterium tuberculosis in humans or animals.
Novelty: Composition used to prevent infection caused by Mycobacterium tuberculosis comprises attenuated Listeria monocytogenes which does not expresses functional specific protein, and expresses Mycobacterium tuberculosis antigen protein

主要类别: 生物医学

细分类别: 病原

申请号码: 10010595

其他

State Of Development

Researchers have genetically modified the bacterial vaccination vector to optimize the expression of immunoprotective proteins and eliminate any vector-mediated toxicity. In animal studies, administration of the novel booster vaccine induced lymphocyte proliferation and TB protection above BCG alone and above BCG plus a viral-based boost.

Background

Tuberculosis (TB) infection remains highly prevalent worldwide. The WHO estimates 1.7 million deaths from TB annually. Africa and Southeast Asia have the highest burden of TB mortality. The persistence of TB infection has promoted the emergence of multi- and extensively drug-resistant (M/XDR) strains, which pose an imminent threat to industrialized nations. The vaccine currently used for TB, BCG, has been widely administered but lacks optimal protection. In fact, a large, carefully conducted meta-analysis by Colditz et al. (1994) estimates the potency of BCG protection to be approximately 50%. Therefore, new vaccines or booster strategies are necessary to combat TB infection. Improvements in the potency of TB vaccination will represent a significant advancement in global health and a step towards eradication of TB.

Additional Technologies by these Inventors

Tech ID/UC Case

22262/2010-657-0

Related Cases

2010-657-0

国家/地区: 美国

欲了解更多信息，请点击这里